ESR1 and breast cancer: The main objective of the present research was to synthesize new series of an isatin-based nucleus and to investigate the candidates as potential ER degraders, inspired by the deficiencies and side effects of first, second, and third generations of endocrine therapeutic agents for the treatment of ER+ BC.